Low- and high-grade bladder cancer appraisal via serum-based proteomics approach

Navneeta Bansal, Ashish Gupta, Satya Narain Sankhwar, Abbas Ali Mahdi

Research output: Contribution to journalArticle

Abstract

Objective: To address the shortcomings of urine cytology and cystoscopy for screening and grading of urinary bladder cancer (BC) we applied a serum-based proteomics approach as a surrogate tactic for rapid BC probing. Methods: This study was performed on 90 sera samples comprising of low-grade (LG, n=33) and high-grade (HG, n=32) BC, and healthy controls (HC, n=25). Two-dimensional gel electrophoresis (2DE) tactic was executed to describe serum proteome. MALDI-TOF-MS (MS) was used to identify the characteristics of aberrantly expressed proteins in 2DE and validated using Western blot (WB) and ELISA approach. Receiver operating characteristics (ROC) curve analysis was also performed to determine the clinical usefulness of these proteins to discriminate among LG, HG and HC cohorts. Results: This comprehensive approach of 2DE, MS, WB and ELISA reveals five differentially expressed proteins. Among them two biomarkers (S100A8 and S100A9) were able to accurately (ROC, 0.946) distinguish 81% of BC (LG. +. HG) cases compared to HC with highest sensitivity and specificity. With a comparable tactic, two biomarkers (S100A8 and S100A4) were able to precisely (ROC, 0.941) discriminate 92% of LG cases from HG with utmost sensitivity and specificity. Conclusions: Serum proteomics probing appears to be an encouraging and least-invasive tactic for screening and grading of BC.

Original languageEnglish (US)
Pages (from-to)97-103
Number of pages7
JournalClinica Chimica Acta
Volume436
DOIs
StatePublished - Sep 25 2014
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Proteomics
Biomarkers
ROC Curve
Screening
Serum
Cytology
Proteins
Proteome
Electrophoresis
Western Blotting
Enzyme-Linked Immunosorbent Assay
Sensitivity and Specificity
Gels
Cystoscopy
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Electrophoresis, Gel, Two-Dimensional
Cell Biology
Urine

Keywords

  • Serum proteomics
  • Two-dimensional gel electrophoresis
  • Urinary bladder cancer

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical
  • Medicine(all)

Cite this

Low- and high-grade bladder cancer appraisal via serum-based proteomics approach. / Bansal, Navneeta; Gupta, Ashish; Sankhwar, Satya Narain; Mahdi, Abbas Ali.

In: Clinica Chimica Acta, Vol. 436, 25.09.2014, p. 97-103.

Research output: Contribution to journalArticle

Bansal, Navneeta ; Gupta, Ashish ; Sankhwar, Satya Narain ; Mahdi, Abbas Ali. / Low- and high-grade bladder cancer appraisal via serum-based proteomics approach. In: Clinica Chimica Acta. 2014 ; Vol. 436. pp. 97-103.
@article{ca0ef9f9042a4942ab3bf97fbb22252c,
title = "Low- and high-grade bladder cancer appraisal via serum-based proteomics approach",
abstract = "Objective: To address the shortcomings of urine cytology and cystoscopy for screening and grading of urinary bladder cancer (BC) we applied a serum-based proteomics approach as a surrogate tactic for rapid BC probing. Methods: This study was performed on 90 sera samples comprising of low-grade (LG, n=33) and high-grade (HG, n=32) BC, and healthy controls (HC, n=25). Two-dimensional gel electrophoresis (2DE) tactic was executed to describe serum proteome. MALDI-TOF-MS (MS) was used to identify the characteristics of aberrantly expressed proteins in 2DE and validated using Western blot (WB) and ELISA approach. Receiver operating characteristics (ROC) curve analysis was also performed to determine the clinical usefulness of these proteins to discriminate among LG, HG and HC cohorts. Results: This comprehensive approach of 2DE, MS, WB and ELISA reveals five differentially expressed proteins. Among them two biomarkers (S100A8 and S100A9) were able to accurately (ROC, 0.946) distinguish 81{\%} of BC (LG. +. HG) cases compared to HC with highest sensitivity and specificity. With a comparable tactic, two biomarkers (S100A8 and S100A4) were able to precisely (ROC, 0.941) discriminate 92{\%} of LG cases from HG with utmost sensitivity and specificity. Conclusions: Serum proteomics probing appears to be an encouraging and least-invasive tactic for screening and grading of BC.",
keywords = "Serum proteomics, Two-dimensional gel electrophoresis, Urinary bladder cancer",
author = "Navneeta Bansal and Ashish Gupta and Sankhwar, {Satya Narain} and Mahdi, {Abbas Ali}",
year = "2014",
month = "9",
day = "25",
doi = "10.1016/j.cca.2014.05.012",
language = "English (US)",
volume = "436",
pages = "97--103",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Low- and high-grade bladder cancer appraisal via serum-based proteomics approach

AU - Bansal, Navneeta

AU - Gupta, Ashish

AU - Sankhwar, Satya Narain

AU - Mahdi, Abbas Ali

PY - 2014/9/25

Y1 - 2014/9/25

N2 - Objective: To address the shortcomings of urine cytology and cystoscopy for screening and grading of urinary bladder cancer (BC) we applied a serum-based proteomics approach as a surrogate tactic for rapid BC probing. Methods: This study was performed on 90 sera samples comprising of low-grade (LG, n=33) and high-grade (HG, n=32) BC, and healthy controls (HC, n=25). Two-dimensional gel electrophoresis (2DE) tactic was executed to describe serum proteome. MALDI-TOF-MS (MS) was used to identify the characteristics of aberrantly expressed proteins in 2DE and validated using Western blot (WB) and ELISA approach. Receiver operating characteristics (ROC) curve analysis was also performed to determine the clinical usefulness of these proteins to discriminate among LG, HG and HC cohorts. Results: This comprehensive approach of 2DE, MS, WB and ELISA reveals five differentially expressed proteins. Among them two biomarkers (S100A8 and S100A9) were able to accurately (ROC, 0.946) distinguish 81% of BC (LG. +. HG) cases compared to HC with highest sensitivity and specificity. With a comparable tactic, two biomarkers (S100A8 and S100A4) were able to precisely (ROC, 0.941) discriminate 92% of LG cases from HG with utmost sensitivity and specificity. Conclusions: Serum proteomics probing appears to be an encouraging and least-invasive tactic for screening and grading of BC.

AB - Objective: To address the shortcomings of urine cytology and cystoscopy for screening and grading of urinary bladder cancer (BC) we applied a serum-based proteomics approach as a surrogate tactic for rapid BC probing. Methods: This study was performed on 90 sera samples comprising of low-grade (LG, n=33) and high-grade (HG, n=32) BC, and healthy controls (HC, n=25). Two-dimensional gel electrophoresis (2DE) tactic was executed to describe serum proteome. MALDI-TOF-MS (MS) was used to identify the characteristics of aberrantly expressed proteins in 2DE and validated using Western blot (WB) and ELISA approach. Receiver operating characteristics (ROC) curve analysis was also performed to determine the clinical usefulness of these proteins to discriminate among LG, HG and HC cohorts. Results: This comprehensive approach of 2DE, MS, WB and ELISA reveals five differentially expressed proteins. Among them two biomarkers (S100A8 and S100A9) were able to accurately (ROC, 0.946) distinguish 81% of BC (LG. +. HG) cases compared to HC with highest sensitivity and specificity. With a comparable tactic, two biomarkers (S100A8 and S100A4) were able to precisely (ROC, 0.941) discriminate 92% of LG cases from HG with utmost sensitivity and specificity. Conclusions: Serum proteomics probing appears to be an encouraging and least-invasive tactic for screening and grading of BC.

KW - Serum proteomics

KW - Two-dimensional gel electrophoresis

KW - Urinary bladder cancer

UR - http://www.scopus.com/inward/record.url?scp=84901989934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901989934&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2014.05.012

DO - 10.1016/j.cca.2014.05.012

M3 - Article

C2 - 24875752

AN - SCOPUS:84901989934

VL - 436

SP - 97

EP - 103

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -